Guangxi Wuzhou Zhongheng Group Co Ltd banner

Guangxi Wuzhou Zhongheng Group Co Ltd
SSE:600252

Watchlist Manager
Guangxi Wuzhou Zhongheng Group Co Ltd Logo
Guangxi Wuzhou Zhongheng Group Co Ltd
SSE:600252
Watchlist
Price: 2.46 CNY -1.6% Market Closed
Market Cap: ¥7.8B

EV/GP

7.6
Current
62%
More Expensive
vs 3-y average of 4.7

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
7.6
=
Enterprise Value
¥6.1B
/
Gross Profit
¥782.2m

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
7.6
=
Enterprise Value
¥6.1B
/
Gross Profit
¥782.2m

Valuation Scenarios

Guangxi Wuzhou Zhongheng Group Co Ltd is trading above its 3-year average

If EV/GP returns to its 3-Year Average (4.7), the stock would be worth ¥1.52 (38% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-46%
Maximum Upside
+78%
Average Downside
2%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 7.6 ¥2.46
0%
3-Year Average 4.7 ¥1.52
-38%
5-Year Average 4.1 ¥1.34
-46%
Industry Average 7.6 ¥2.44
-1%
Country Average 13.6 ¥4.38
+78%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CN
Guangxi Wuzhou Zhongheng Group Co Ltd
SSE:600252
7.8B CNY 7.6 -21.5
US
Eli Lilly and Co
NYSE:LLY
883B USD 17.4 44.1
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 8.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 6.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 7.4 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 5.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 5.3 12.1
US
Pfizer Inc
NYSE:PFE
151.8B USD 4.2 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 4.3 16.6
P/E Multiple
Earnings Growth PEG
CN
Guangxi Wuzhou Zhongheng Group Co Ltd
SSE:600252
Average P/E: 22.4
Negative Multiple: -21.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.1
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

Lower than 71% of companies in China
Percentile
29th
Based on 6 967 companies
29th percentile
7.6
Low
0 — 8
Typical Range
8 — 23.3
High
23.3 —
Distribution Statistics
China
Min 0
30th Percentile 8
Median 13.6
70th Percentile 23.3
Max 17 898 541.1

Guangxi Wuzhou Zhongheng Group Co Ltd
Glance View

Market Cap
7.8B CNY
Industry
Pharmaceuticals

Guangxi Wuzhou Zhongheng Group Co Ltd is an intriguing player nestled in China's vibrant industrial landscape. The company, with its roots firmly planted in the southeastern province of Guangxi, has carved a niche for itself in the pharmaceutical and health products sector. Since its establishment, Zhongheng Group has methodically expanded its operations, establishing a robust portfolio that includes everything from the cultivation and processing of Chinese medicinal herbs to the development and manufacturing of pharmaceutical products. This vertical integration ensures quality control from start to finish and allows the company to create an array of products, catering to a diverse market that values traditional Chinese medicine as much as modern health solutions. Zhongheng Group's revenue model hinges on its ability to efficiently blend traditional expertise with modern pharmaceutical practices, capitalizing on the increasing demand for health and wellness products. Through its comprehensive supply chain, the company can produce a competitive range of cost-effective pharmaceuticals and health supplements, positioning itself for profitability in a growing market. Additionally, the company's strategic emphasis on research and development facilitates innovation, allowing for the introduction of new products that meet evolving consumer needs. By maintaining a dynamic array of offerings and leveraging its integrated operations, Guangxi Wuzhou Zhongheng Group Co Ltd continues to navigate the competitive landscape of the pharmaceutical industry, ensuring its place as a key player in China's economic tapestry.

Intrinsic Value
1.32 CNY
Overvaluation 46%
Intrinsic Value
Price ¥2.46
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett